

RNS Number : 3330T
EKF Diagnostics Holdings PLC
19 November 2013

**EKF Diagnostics Holdings plc
("EKF" or "the Company")**

Acute Kidney Injury marker development

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care diagnostics business, announces that the development of a Point of Care platform for Acute Kidney Injury is progressing well with testing on clinical samples due to start in early 2014 as the next phase in product development.

EKF has been working in collaboration with Carclo Diagnostic Solutions Ltd ("Carclo Diagnostics"), a subsidiary of Carclo plc, to produce a novel Point of Care device for detecting Acute Kidney Injury, providing an alternative to standard lateral flow testing. Testing on clinical samples of EKF's Acute Kidney Injury marker (Pi-GST) and an assay based on Carclo Diagnostic's micropoc-pro platform are due to commence in early 2014 and should complete by mid-year.

Julian Baines, CEO of EKF commented: "Whilst this project is still at a very early stage, I am pleased with the progress we've made with Carclo Diagnostics in developing a novel point of care test as an alternative to the standard lab-based tests for Acute Kidney Injury."

Enquiries:

EKF Diagnostics Holdings plc
David Evans, Executive Chairman
Julian Baines,
CEO

Tel: 029 2071 0570
Mob: 07740 084452
Mob: 07788 420 859

Canaccord Genuity Limited
Lucy Tilley / Henry Fitzgerald-O'Connor
/ Julian Feneley

Tel: 020 7523 8000

Walbrook PR Limited
Paul McManus

Paul Cornelius

Tel: 020 7933 8780
Mob: 07980 541 893 or
paul.mcmanus@walbrookpr.com
Mob: 07866 384 707 or
paul.cornelius@walbrookir.com

About EKF Diagnostics Holdings plc - www.ekfdiagnostics.com

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition

of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in October 2010), Argutus Medical Limited (acquired in December 2010) and Stanbio Laboratory L.P. (acquired in June 2011). In March 2013 EKF established a new subsidiary, EKF Molecular Diagnostics Ltd, to focus on molecular and companion diagnostics and acquired 360 Genomics Ltd, a business that develops diagnostics technologies for cancer gene detection.

The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focussing on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

In May 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.

This information is provided by RNS
The company news service from the London Stock Exchange

END

NRAGGGCGGUPWGMR admin Acute Kidney Injury marker development 21301776 A Tue, 11/19/2013 - 07:00 Company Announcement - General EKF